Piper Sandler lowered the firm’s price target on Aquestive Therapeutics (AQST) to $5 from $8 and keeps an Overweight rating on the shares.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AQST:
- Aquestive Therapeutics reports Q1 EPS (24c), consensus (16c)
- Aquestive Therapeutics Submits NDA for Anaphylm
- Aquestive Therapeutics, Inc. (AQST) Q1 Earnings Cheat Sheet
- Buy Rating Affirmed for Aquestive Therapeutics Amid Promising Anaphylm Developments and Strategic Progress
- Optimistic Buy Rating for Aquestive Therapeutics Driven by Anaphylm’s Promising NDA Submission and Clinical Success
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue